ANTIBIOTIC RESISTANCE & CA-MRSA Present by Manita Attasuriyanan, MD.

Slides:



Advertisements
Similar presentations
Hospital-acquired and community-acquired MRSA in hospitals
Advertisements

Game plan Lecture Antibiotics Antibiotic resistance Gene transfer Transformation Transduction Conjugation Lab Lab Exam Pre-lab Transformation.
Mechanisms of Genetic Variation 1 16 Copyright © McGraw-Hill Global Education Holdings, LLC. Permission required for reproduction or display.
MRSA: Epidemiology & Treatment. MRSA: Epidemiology & Treatment: Points of this Talk - MRSA is primarily healthcare-associated - Community-acquired MRSA.
Bacterial Drug Resistance Discovery of penicillin –Sir Alexander Fleming. –Accidental mold contamination. Chinese, Egyptians, Europeans used moldy.
The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
Choosing Antimicrobials in Special Situations. Additional considerations in making a final antibiotic selection Site of action – (Will the antibiotic.
Introduction to Antibiotics 1 st yr( Respiratory block) Prof. Azza Elmedany.
The Increasing Public Health Exigency of Antimicrobial Resistance Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
MRSA Update 2013 David K. Hong, MD Pediatrics/Infectious Diseases &
MRSA.
Methicillin Resistant Staphylococcus aureus (MRSA) in the Community: Epidemiology and Management Rachel Gorwitz, MD, MPH Division of Healthcare Quality.
MRSA Moving from Infection Control to Infection Prevention: A Journey through MRSA PATIENTS C DIFF Joan M. Ivaska, BS, MPH, CIC.
Antimicrobial Susceptibility Testing – Part II
Lecture 3 MRSA Methicillin resistant S. aureus
1 Antimicrobial Therapy Chemotherapy: any treatment of patient with chemicals to treat a condition. –Now word associated with cancer treatment –Our focus.
Antimicrobials 3: Resistance Dr Fiona Walsh. Objectives of lecture Genetics of resistance Mechanisms of resistance Current and future problems.
CHEMOTHERAPY ANTIBIOTICS Chemical substances produced by microorganisms and have the capacity to inhibit or destroy other organisms. ANTIBIOTICS Chemical.
MRSA Barbara Kilian, MD St.Luke’s Roosevelt Academic Associate Program Fall 2005.
1 Antimicrobial Therapy Chemotherapy: any treatment of patient with chemicals to treat a condition. –Now word associated with cancer treatment –Our focus.
Outpatient management of skin and soft tissue infections, specifically for community-associated MRSA Patient presents with signs/ symptoms of skin infection:
Epidemiology and Control of Methicillin-Resistant Staphylococcus aureus in hospitals Maria Kapi,MD Registrar of Medical Microbiology Laiko General Hospital.
Antibiotics Biotechnology II. Univ S. Carolina Antibiotics Disrupt Cell Wall Synthesis, Protein Synthesis, Nucleic Acid Synthesis and Metabolism.
ANTIMICROBIAL RESISTANCE Edith Blondel-Hill MD,FRCP Medical Microbiologist/Infectious Diseases Specialist Medical Director Interior Health Antimicrobial.
Community- Associated MRSA Maha Assi, MD, MPH. MRSA Hits the Media October 16, 2007 October 16, 2007 Lead story on MRSA Lead story on MRSA “superbug killing.
Methicillin-Resistant Staphylococcus aureus (MRSA)
CHAPTER 20 ANTIBIOTIC RESISTANCE
Genetic transfer and recombination
MRSA and the Cook County Jail: Analysis of Isolates That May Be From a Reservoir of Community- Associated Infections Lena Kuo, MD, Robert Daum, MD, Susan.
(methicillin-resistant Staphylococcus aureus)
Mechanisms of antimicrobial action directed against the bacterial cell wall and corresponding resistance mechanisms M-4 Advanced Therapeutics Course.
Warren S. Joseph, DPM, FIDSA Roxborough Memorial Hospital, Phila., PA
The evolution of antibiotic resistance Rob Knell / Lars Chittka.
Lilly Immergluck, MD Associate Professor of Pediatrics
Microbiology Antimicrobial Susceptibility Testing – Part I Karen Honeycutt, M.Ed., MT(ASCP)SM CLS 418 Clinical Microbiology Student Laboratory Session.
ANTIMICROBIAL RESISTANCE
Antibiotic Resistance
Microbiology- a clinical approach by Anthony Strelkauskas et al Chapter 20: Antibiotic resistance.
AMINOGLYCOSIDES The different members of this group share many properties in common. The different members of this group share many properties in common.
CHEMOTHERAPY  Antimicrobial chemotherapy  Antiviral chemotherapy  Antiparasitic Drugs  Cancer Chemotherapy.
Evidence-based Medicine. Case Presentation 27 yo AA male presents to clinic with 3 days of pain and swelling in right leg First noted several spider bites.
Community-Associated Methicillin-Resistant Staphylococcus aureus Ruth Lynfield, M.D. Minnesota Department of Health.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
Batterjee Medical College. Dr. Manal El Said Department Head of Microbiology Antimicrobial Drugs: Mechanism of Action.
ANTIMICROBIAL AGENTS. ANTIBIOTICS ANTIMICROBIAL AGENTS CHEMOTHERAPEUTIC AGENTS.
Burton's Microbiology for the Health Sciences Chapter 9
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Bacteria and antibiotics Page refs for this section = Textbook p
THINGS TO BE DISCUSSED Multi resistance antimicrobials Effects of some Antibiotics Research article Case study Future Horizons.
Cheryl Meddles-Torres, DNP, RN, FNP-C Shuang Hu
Antibiotics I.. Consequences of inappropriate antibiotic therapy Inappropriate antibiotic therapy can lead to increases in:Inappropriate antibiotic therapy.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
Prokaryotic Diversity and Molecular Genetics Biol 103 Diversity of Life.
Bacterial Genetics. Vocabulary Binary fission Exponential growth Gram positive Gram negative Pathogen Antibiotic Selection pressure Adaptation Mutation.
PRINCIPLES OF ANTIBIOTIC THERAPY
IMPORTANT ANTIBIOTICS AND ANTIMICROBIAL RESISTANCE A Presentation By Ms R.Venkatajothi, MSc., MPhil, PhD Senior Lecturer Department of Microbiology Faculty.
ANTIMICROBIAL AGENTS.
Community-Associated MRSA Infections
Adaptation & Selection
Antibiotic Resistance
Antibiotic Resistance
Lecture 1 Antimicrobial drugs.
General considerations of antimicrobial agents (抗微生物药物概论)
Antibiotic Resistance
Advisor: Dr. Stephanie Booth
Drug Resistance Bacteria are considered resistant to an antibiotic if the maximal level of that antibiotic that can be tolerated by the host does not halt.
Chemotherapeutic Medicine
TRAINING PRESENTATION
Killing Bacteria Ain’t Easy
Presenter: Zipporah Machuki
Presentation transcript:

ANTIBIOTIC RESISTANCE & CA-MRSA Present by Manita Attasuriyanan, MD.

 Antibiotic resistance  Community-associated MRSA

 Many bacterial have developed antibiotic resistance  80% of Staphylococcus resistant to penicillin  “Superbugs” resistant to all antibiotics  Multi-drug resistant tuberculosis  Misuse of antibiotics accelerates rates of resistance

Penicillin Cephalosporin Fluoroquinolone Carbapenem Discovery void

Resistance mechanisms GeneticIntrinsicAcquiredBiochemicalEnzymatic inactivationAlterated targetEfflux pumpDecrease permeability

Natural resistance  Chromosomic genetic support  Affect almost all species strains  Existed before antibiotic use e.g. Enterobacter sp. - amoxicillin Acquired resistance (mutation)  Chromosomic, plasmid or transposon genetic support  Affects a fraction of strains  Increased with antibiotic use e.g. extended spectrum beta-lactamase producing E. coli

Intrinsic Mutation Horizontal gene tranfer Conjugation Transduction Transformation

 Transmission of resistance genes via plasmid exchange.  Resistance spreads much faster than simple mutation and vertical evolution would permit.

 Transduction: virus transfers gene.  Transformation: DNA released from a bacterium is picked up by a new cell.

New Resistant Bacteria Mutations XX Susceptible Bacteria Resistant Bacteria Resistance Gene Transfer

Resistant Strains Rare x x Resistant Strains Dominant Antimicrobial Exposure x x x x x x x x x x

1. Inactivation of drug:  -lactamases 2. Alteration of the ATB target - Penicillin binding proteins - Ribosomes 3. Efflux pump 4. Decreased permeability

 Enzymes can destroy or disable antibiotics.  For example,  -lactamase hydrolyzes  -lactam ring of penicillins.  Without a  -lactam ring, penicillins ineffective.

 Bacteria can modify the ATB target to escape its activity.  Bacteria must change structure of the target but the modified target must still be able to function. 2.1 Mutation of the gene coding for the target protein 2.2 Importing a gene that codes for a modified target e.g. MRSA (methicillin- resistant - S. aureus ), similar to PBP (penicillin- binding- protein)

 PBPs are targets for penicillin.  Bacteria have PBPs in their plasma membranes.  MRSA has acquired a gene (mec A) that codes for a different PBP. - Different 3-dimensional structure - MRSA less sensitive to penicillins

 MRSA is resistant to all β-lactam antibiotics, cephalosporins, and carbapenems. - It is a very dangerous pathogen particularly in burn patients  Streptococcus pneumoniae also modifies PBP. - It can make as many as five different types of PBP. - It does this by rearranging, or shuffling, the genes.

 Bacterial ribosomes are a primary target for antibiotics - Different antibiotics affect them in different ways  Resistance can be the result of modification of ribosomal RNA so it is no longer sensitive  Some organisms use target modification in conjunction with efflux pumps - Resistance is even more effective

 Efflux pumping is an active transport mechanism. › It requires ATP  Efflux pumps are found in: › The bacterial plasma membrane › The outer layer of gram-negative organisms  Pumping keeps the concentration of antibiotic below levels that would destroy the cell

 Genes that code for efflux pumps are located on plasmids and transposons.  Transposons are sequences of DNA that can move or transpose move themselves to new positions within the genome of a single cell.  Transposones: › Readily acquired by non-resistant bacteria › Transforms them into resistant bacteria

 As a way of keeping ATB out  Bacteria turn off production of porin and other membrane channel proteins.

Enzymatic inactivation  lactam Aminoglycoside Macrolide Alternated target  lactam Quinolone Aminoglycoside Vancomycin Macrolide TMP/SMP Efflux pump Tetracycline Quinolone Macrolide Decrease permiability  lactam Aminoglycoside

Increasing resistance  Inpatient (MRSA, VRE, Pseudomonas, Acinetobacter)  Outpatient (E. coli, CA-MRSA, S. pneumoniae) Clinical ConditionMortality Risk MRSA vs. MSSA bacteremia MRSA vs. MSSA SSI VRE vs. VSE bacteremia Emergence of resistant Pseudomonas Enterobacter resistant to 3 rd gen ceph MDR-Acinetobacter vs. non-MDR Acin bacteremia Clin Infect Dis 2003;36: Arch Intern Med 1999;159: Clin Infect Dis 2003;36: Arch Intern Med 2002;162: Clin Infect Dis 2005;41: Infect Control Hosp Epidemiol 2007;28:713-9

 Staphylococcus aureus: common cause of infection in the community  Methicillin-resistant Staphylococcus aureus (MRSA):  Increasingly important cause of healthcare- associated infections since 1970s  In 1990s, emerged as cause of infection in the community

 CDC definition: early than 48 hrs after admission  CA-MRSA do not transferred from the hospitals  Patients usually have no previous contact with healthcare centers  Cause mostly skin and soft tissue infections  rarely cause URI or UTI, which are common with healthcare strains

Clin infect Dis Aug 41 (supplement 4)

 Difference in clinical manifestations may be due to the presence in community strains of toxins e.g. PVL or Panton Vanlentine Leukocidine, that causes severe inflammation  Molecular markers for CA-MRSA: - SCC (staphylococcus cassette chromosome) mec type IV, V - PVL

MRSA in Healthcare MRSA in the Community Prevalent genotypes (U.S.)USA100, USA200 USA300, USA400 Antimicrobial resistanceMultiple agents Few agents SCCmec (genetic element carrying mecA resistance gene) Types I-IIITypes IV, V PVL toxin geneRareCommon

 MRSA culture in outpatient setting or 1 st 48 hours of hospitalization AND patient lacks risk factors for healthcare-associated MRSA:  Hospitalization  Surgery  Long-term care  Dialysis  Indwelling devices  History of MRSA

 Often first detected as clusters of abscesses or “spider bites”  Various settings  Sports participants  Inmates in correctional facilities  Military recruits  Daycare attendees  Native Americans / Alaskan Natives  Men who have sex with men  Tattoo recipients

 Crowding  Frequent contact  Compromised skin  Contaminated surfaces and shared items  Poor hygiene  Antimicrobial use

Disease Syndrome (%) Skin/soft tissue1,266 (77%) Wound (Traumatic) 157 (10%) Urinary Tract Infection 64 (4%) Sinusitis 61 (4%) Bacteremia 43 (3%) Pneumonia 31 (2%) Fridkin et al NEJM 2005;352:

 MRSA belongs in the differential diagnosis of skin and soft tissue infections (SSTI) compatible with S. aureus infection: Abscesses, pustular lesions, “boils” “Spider bites” Cellulitis?

MRSA should also be considered in differential diagnosis of severe disease compatible with S. aureus infection e.g. osteomyelitis, empyema thoracic, necrotizing pneumonia, septic arthritis, endocarditis, sepsis syndrome, necrotizing fasciitis, purpura fulminans

 I&D should be routine for purulent skin lesions  Obtain material for culture  No data to suggest molecular typing or toxin- testing should guide management  Empiric antimicrobial therapy may be needed  Alternative agents have +’s and –’s: More data needed to identify optimal strategies

Antimicrobial Selection (SSTIs)  Alternative agents Clindamycin – Potential for inducible resistance, Relatively higher risk of C. difficile associated disease? TMP/SMX – Group A strep isolates commonly resistant Tetracyclines – Not recommended for <8 yo Rifampin – Not as a single agent Linezolid – Expensive, Potential for resistance with inappropriate use

Antimicrobial Selection (SSTIs)  Not optimal for MRSA (High prevalence of resistance or potential for rapid development of resistance) - Macrolides - Fluoroquinolones

Beta-Lactam Modified from David Spach, MD Cell Wall Cell Membrane Alternative Penicillin Binding Protein PBP2a DNA

IntravenousOral - Vancomycin* - Linezolid* - Daptomycin* - Tigecycline* - Quinupristin/dalfopristin * - TMP-SMX - Minocycline/Doxy - Clindamycin** - Fluoroquinolone - Linezolid* *FDA approved for MRSA **test for inducible resistance if erythromycin–R and clindamycin-S Rifampin should not be routinely used in combination for SSTI and NEVER alone due to rapid emergence of resistance.

So what are non-vanco options? Linezolid  Pros  100% oral bioavailability  Benefit in MRSA PNA?  Protein synthesis inhibitor  Cons  Static drug  Limited data in bacteremia and endocarditis  Adverse events ▪Marrow suppression ▪Serotonin syndrome ▪Lactic acidosis ▪Optic neuritis, peripheral neuropathy, Bell’s palsy  Cost Daptomycin  Pros  Cidal drug  Approved for bacteremia and right sided endocarditis  Cons  Not active in the lung  Parenteral only  Decreased susceptibility to vancomycin associated with decreased susceptibility to daptomycin  Emergence of resistance on therapy  Cost

 The most important contributing factor for resistance is overuse.  A good example is prescribing antibiotics that don’t kill viruses for the common cold.  These antibiotics do destroy the normal flora.  Opportunistic pathogens that are resistant survive and can take hold.

 For the acquisition of resistance › compromised people › extremely pathogenic organism › large amounts of different ATB use  Increased use of antibiotics  resistance  So hospital is a place where resistance can develop rapidly.

 The potential for global antibiotic resistance is real due to: > overuse of ATB > improper adherence to hospital infection control protocols > difficulty finding new ATB > ease of worldwide travel